USPTO serial 77860437
PREVENTIV MEASURES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- RAUEN, JAMES
- Law office
- TMEG LAW OFFICE 109 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with PREVENTIV MEASURES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Marcia Ireland Rosenfeld
MARCIA IRELAND ROSENFELD MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP300 S WACKER DR STE 3200CHICAGO, IL 60606-6709UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Labels sold as an integral component of pharmaceuticals, namely, alkalizing agents, analgesics and anesthetics, antacids, anticholinergics, anti-infectives, anti-inflammatory agents, anticonvulsants, antiemetics, anxiolytics, blood modifiers, cardiovasculars, diuretics, hormones, diluents, oncolytics, transplantation agents, imaging agents, vascular targeting agents, cancer treatments, and vascular disease treatments; Labels sold as an integral component of pre-filled syringes sold filled with alkalizing agents, labels sold as an integral component of pre-filled syringes sold filled with analgesics and anesthetics, labels sold as an integral component of pre-filled syringes sold filled with antacids, labels sold as an integral component of pre-filled syringes sold filled with anticholinergics, labels sold as an integral component of pre-filled syringes sold filled with anti-infectives, labels sold as an integral component of pre-filled syringes sold filled with anti-inflammatory agents, labels sold as an integral component of pre-filled syringes sold filled with anticonvulsants, labels sold as an integral component of pre-filled syringes sold filled with antiemetics, labels sold as an integral component of pre-filled syringes sold filled with anxiolytics, labels sold as an integral component of pre-filled syringes sold filled with blood modifiers, labels sold as an integral component of pre-filled syringes sold filled with cardiovasculars, labels sold as an integral component of pre-filled syringes sold filled with diuretics, labels sold as an integral component of pre-filled syringes sold filled with hormones, labels sold as an integral component of pre-filled syringes sold filled with diluents, labels sold as an integral component of pre-filled syringes sold filled with oncolytics, labels sold as an integral component of pre-filled syringes sold filled with transplantation agents, labels sold as an integral component of pre-filled syringes sold filled with imaging agents, labels sold as an integral component of pre-filled syringes sold filled with vascular targeting agents, labels sold as an integral component of pre-filled syringes sold filled with cancer treatments, and labels sold as an integral component of pre-filled syringes sold filled with vascular disease treatments; Labels sold as an integral component of injectable drugs and therapeutic solutions for the treatment of cancer and vascular diseases; labels sold as an integral component of injectable drugs and therapeutic solutions for the treatment of pain; labels sold as an integral component of injectable drugs and therapeutic solutions for the treatment of infections; labels sold as an integral component of injectable drugs and therapeutic solutions for the treatment of cardiovascular disease; labels sold as an integral component of injectable drugs and therapeutic solutions for the treatment of hormonal imbalances; labels sold as an integral component of injectable drugs and therapeutic solutions for the treatment of heartburn; labels sold as an integral component of injectable drugs and therapeutic solutions for imaging; Labels sold as an integral part of injectable drugs and therapeutic solutions for the treatment of cancer and vascular diseases sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; Labels sold as an integral part of injectable drugs and therapeutic solutions for the treatment of pain sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; Labels sold as an integral part of injectable drugs and therapeutic solutions for the treatment of infections sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; Labels sold as an integral part of injectable drugs and therapeutic solutions for the treatment of cardiovascular disease sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; Labels sold as an integral part of injectable drugs and therapeutic solutions for the treatment of hormonal imbalances sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; Labels sold as an integral part of injectable drugs and therapeutic solutions for the treatment of heartburn sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; Labels sold as an integral part of injectable drugs and therapeutic solutions for imaging sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 29, 2010 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Sep 29, 2010 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Feb 4, 2010 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 4, 2010 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 4, 2010 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 3, 2010 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 5, 2009 | MPMK | NOTICE OF PSEUDO MARK MAILED | — |
| Nov 4, 2009 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 2, 2009 | NWAP | NEW APPLICATION ENTERED | — |